First Gene-Edited Islet Cell Transplant Shows Success in Diabetes

Published on: ScienceAlert

For the first time, a type 1 diabetes patient has begun producing insulin after receiving gene-edited islet cells that avoid immune rejection without the need for immunosuppressant drugs. The cells, modified with CRISPR and injected into the patient’s forearm muscle, responded to glucose levels for 12 weeks. This proof-of-concept, reported in The New England Journal of Medicine, marks a major step toward safer and more effective diabetes cell therapies.

👉 Read the full article: First-Of-Its-Kind Cell Transplant Brings a Cure for Diabetes Closer

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.